Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547898 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea
A Phase 3 study of HIV Associated Diarrhea, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 374
- Enrollment target
- 20
- Study locations
NCT00547898 is a Phase 3 study of HIV Associated Diarrhea that has completed, run by Bausch Health Americas. The registered enrollment target is 374 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT00547898, a Phase 3 study of HIV Associated Diarrhea, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 374 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, parallel-group, placebo-controlled, multi-center study. This study will compare an investigational new drug (crofelemer) to placebo for the control of HIV-associated diarrhea. The first stage of the study will determine the optimal dose of study drug based on safety and response to therapy and the second stage will evaluate further the effectiveness of the optimal dose.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Crofelemer 125 mg
- DRUG Crofelemer 250 mg
- DRUG Crofelemer 500 mg
Study Locations (20)
California
- - Bakersfield
- - Beverly Hills
- - Beverly Hills
- - Fountain Valley
- - Long Beach
- - Los Angeles
- - Los Angeles
- - Los Angeles
- - Oakland
- - Palm Springs
- - San Diego
- - San Francisco
- - San Mateo
Florida
- - Daytona Beach
- - Fort Lauderdale
- - Fort Lauderdale
Alabama
- - Huntsville
Arizona
- - Phoenix
Arkansas
- - Little Rock
Colorado
- - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 374 participants |
| Start Date | 2007-10 |
| Est. Completion | 2011-07-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00547898
The ClinicalTrials.gov registry entry for NCT00547898 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 374 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Associated Diarrhea appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00547898 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00547898 about?
NCT00547898 is a clinical study titled "Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea". This is a randomized, double-blind, parallel-group, placebo-controlled, multi-center study. This study will compare an investigational new drug (crofelemer) to placebo for the control of HIV-associated diarrhea. The first stage of the study will determine the optimal dose of study drug based on safe...
What is the current status of trial NCT00547898?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 374 participants. The study started on 2007-10. Estimated completion is 2011-07-11.
What conditions does trial NCT00547898 study?
This clinical trial studies the following conditions: HIV Associated Diarrhea.
What interventions are being tested in trial NCT00547898?
The interventions under investigation include: Placebo (DRUG), Crofelemer 125 mg (DRUG), Crofelemer 250 mg (DRUG), Crofelemer 500 mg (DRUG).
Who is sponsoring clinical trial NCT00547898?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00547898 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.